Sabinsa's flagship combination product, Curcumin C3 Complex® with BioPerine® (525mg/2.5 mg twice a day, 14 days), was used as adjuvant therapy for COVID-19 in a double-blind, randomized controlled clinical trial conducted on COVID-19 patients in India, where the wide-spread virus infection has strained the healthcare system.
Sabinsa’s founder and chairman, Dr. Muhammed Majeed, announced today the promotion of Dr. Umar Jan to President of European Operations.
- Press Release
Sabinsa has opened two new satellite offices in the UK and in Spain to support customers in Europe. The Spanish office will service Spain, Portugal, the Iberian Peninsula, Southern France, and Northwestern Africa. The UK office will support customers in the UK and Ireland in navigating changes and challenges brought about by Brexit.
Sabinsa’s intellectual property portfolio now includes 308 separate patents granted across the world. The most recent patents granted include several from Australia, Canada, Europe, and the USA. Sabinsa’s patent portfolio includes composition, use and process patents. Many are for various aspects of category leader ingredients such as LactoSpore®, DigeZyme® and Curcumin C3 Complex®; others are for relatively new, up and coming ingredients such as Nigellin® and Sabroxy®.
- Press Release
Sabinsa has successfully completed the audit for several of its natural cosmetic ingredients as conforming to COSMOS standards, verified by Ecocert Greenlife: Cococin™ (Cocos nucifera liquid Endosperm), Saberry® (Emblica officinalis fruit extract) and Nigellin® Amber (Black seed extract).